Silver Creek Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Silver Creek Pharmaceuticals General Information

Description

Operator of a biotechnology firm intended to develop therapies that improve the body's healing response and repair damaged tissue. The company offers novel regenerative medicines that stimulate stem cell-based regeneration of cardiovascular tissues after a cardiac infarction, providing patients with the required therapies to protect or repair heart tissue following a heart attack.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 329 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (833)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 329 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (833)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Silver Creek Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 01-Jan-2025 Completed Clinical Trials - Phase 2
7. Later Stage VC 11-Feb-2022 Completed Clinical Trials - Phase 2
6. Accelerator/Incubator Completed Clinical Trials - Phase 2
5. Secondary Transaction - Private 10-May-2019 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 05-Feb-2018 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 01-Apr-2015 Completed Clinical Trials - Phase 2
2. Grant 15-Mar-2015 $221K $19M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 21-Apr-2014 $19M $19M Completed Clinical Trials - Phase 2
To view Silver Creek Pharmaceuticals’s complete valuation and funding history, request access »

Silver Creek Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 19,836,652 $0.000100 $0.07 $1 $1 1x $1 49.59%
To view Silver Creek Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Silver Creek Pharmaceuticals Patents

Silver Creek Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112345-A1 Methods of treatment using igf-1 chimeric proteins Pending 20-Nov-2024
AU-2024214275-A1 Methods of treatment using igf-1 chimeric proteins Pending 02-Feb-2023
EP-4658295-A2 Methods of treatment using igf-1 chimeric proteins Pending 02-Feb-2023
EP-4658295-A4 Methods of treatment using igf-1 chimeric proteins Pending 02-Feb-2023
US-20260226132-A1 Methods of treatment using igf-1 chimeric proteins Pending 02-Feb-2023 C07K14/65
To view Silver Creek Pharmaceuticals’s complete patent history, request access »

Silver Creek Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Silver Creek Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Catalytik Group Venture Capital Minority
National Heart, Lung, and Blood Institute Government
QB3 Accelerator/Incubator Minority
To view Silver Creek Pharmaceuticals’s complete investors history, request access »

Silver Creek Pharmaceuticals FAQs

  • When was Silver Creek Pharmaceuticals founded?

    Silver Creek Pharmaceuticals was founded in 2010.

  • Where is Silver Creek Pharmaceuticals headquartered?

    Silver Creek Pharmaceuticals is headquartered in South San Francisco, CA.

  • What is the size of Silver Creek Pharmaceuticals?

    Silver Creek Pharmaceuticals has 12 total employees.

  • What industry is Silver Creek Pharmaceuticals in?

    Silver Creek Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Silver Creek Pharmaceuticals a private or public company?

    Silver Creek Pharmaceuticals is a Private company.

  • What is Silver Creek Pharmaceuticals’s current revenue?

    The current revenue for Silver Creek Pharmaceuticals is .

  • How much funding has Silver Creek Pharmaceuticals raised over time?

    Silver Creek Pharmaceuticals has raised $57.1M.

  • Who are Silver Creek Pharmaceuticals’s investors?

    Catalytik Group, National Heart, Lung, and Blood Institute, and QB3 have invested in Silver Creek Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process